Pharmacokinetics of amphotericin B lipid complex in critically ill patients undergoing continuous venovenous haemodiafiltration

Malone, Maeve E.; Corrigan, Owen I.; Kavanagh, Pierce V.; Gowing, Caitriona M; Donnelly, Maria; D’Arcy, Deirdre M.

doi:10.1016/j.ijantimicag.2013.06.011

Cited by 12 publications

(5 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…No significant influence of CVVH on the pharmacokinetics of amphotericin B (AMB) lipid complexes has been found (Bellmann et al, 2003). CVVHDF had no clinically significant effect on the pharmacokinetics of AMB following administration of AMB lipid complexes (Malone et al, 2013). A standard dose of these antimicrobials can be recommended for patients during CRRT.…”

Section: Antimicrobials Which Do Not Need Dosing Adjustmentmentioning

confidence: 99%

Recommendation of Antimicrobial Dosing Optimization During Continuous Renal Replacement Therapy

Xia

et al. 2020

Front. Pharmacol.

View full text Add to dashboard Cite

Continuous Renal Replacement Therapy (CRRT) is more and more widely used in patients for various indications recent years. It is still intricate for clinicians to decide a suitable empiric antimicrobial dosing for patients receiving CRRT. Inappropriate doses of antimicrobial agents may lead to treatment failure or drug resistance of pathogens. CRRT factors, patient individual conditions and drug pharmacokinetics/pharmacodynamics are the main elements effecting the antimicrobial dosing adjustment. With the development of CRRT techniques, some antimicrobial dosing recommendations in earlier studies were no longer appropriate for clinical use now. Here, we reviewed the literatures involving in new progresses of antimicrobial dosages, and complied the updated empirical dosing strategies based on CRRT modalities and effluent flow rates. The following antimicrobial agents were included for review:

show abstract

Section: Antimicrobials Which Do Not Need Dosing Adjustmentmentioning

confidence: 99%

Recommendation of Antimicrobial Dosing Optimization During Continuous Renal Replacement Therapy

Xia

et al. 2020

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…For example, they were reported to be (i) less susceptible to bacterial resistance and (ii) to be amenable to functionalization to optimize activity against preferred targets [37]. Moreover, nanoparticles-based agents might be stimulated in various ways, including temperature, pH or magnetic fields [38]; in addition, they are resistant to the biodegradation processes and possess the ability to penetrate bacterial cell membranes and cross some barriers that are typically non-permeable for conventional therapeutic agents [39]. Importantly, association of an antibiotic with a NP may display a cumulative effect on pathogenic microorganisms and thus overcome the resistance mechanisms and lower effective drug doses thereby reducing undesirable side effects [40].…”

Section: Nanoparticles and Nanomaterials As Antimicrobial Agentsmentioning

confidence: 99%

Nanoantibiotics containing membrane-active human cathelicidin LL-37 or synthetic ceragenins attached to the surface of magnetic nanoparticles as novel and innovative therapeutic tools: current status and potential future applications

et al. 2020

View full text Add to dashboard Cite

Nanotechnology-based therapeutic approaches have attracted attention of scientists, in particular due to the special features of nanomaterials, such as adequate biocompatibility, ability to improve therapeutic efficiency of incorporated drugs and to limit their adverse effects. Among a variety of reported nanomaterials for biomedical applications, metal and metal oxide-based nanoparticles offer unique physicochemical properties allowing their use in combination with conventional antimicrobials and as magnetic field-controlled drug delivery nanocarriers. An ever-growing number of studies demonstrate that by combining magnetic nanoparticles with membrane-active, natural human cathelicidin-derived LL-37 peptide, and its synthetic mimics such as ceragenins, innovative nanoagents might be developed. Between others, they demonstrate high clinical potential as antimicrobial, anti-cancer, immunomodulatory and regenerative agents. Due to continuous research, knowledge on pleiotropic character of natural antibacterial peptides and their mimics is growing, and it is justifying to stay that the therapeutic potential of nanosystems containing membrane active compounds has not been exhausted yet.

show abstract

“…This study is not shown in Table 3 because it was conducted in patients with continuous venovenous hemodiafiltration. The authors of this study report a half-life of 48.2 h, a clearance of 31 L/h, and a volume of distribution of 1607 L after a dose of 5 mg/kg bodyweight of ABLC [8].…”

Section: Amphotericin Bmentioning

confidence: 70%

Systemic and Target-Site Pharmacokinetics of Antiparasitic Agents

Jalali

Zeitlinger

2020

Clin Pharmacokinet

View full text Add to dashboard Cite

About one-sixth of the world's population is affected by a neglected tropical disease as defined by the World Health Organization and Center for Disease Control. Parasitic diseases comprise most of the neglected tropical disease list and they are causing enormous amounts of disability, morbidity, mortality, and healthcare costs worldwide. The burden of disease of the top five parasitic diseases has been estimated to amount to a total 23 million disability-adjusted life-years. Despite the massive health and economic impact, most drugs currently used for the treatment of parasitic diseases have been developed decades ago and insufficient novel drugs are being developed. The current review provides a compilation of the systemic and target-site pharmacokinetics of established antiparasitic drugs. Knowledge of the pharmacokinetic profile of drugs allows for the examination and possibly optimization of existing dosing schemes. Many symptoms of parasitic diseases are caused by parasites residing in different host tissues. Penetration of the antiparasitic drug into these tissues, the target site of infection, is a prerequisite for a successful treatment of the disease. Therefore, for the examination and improvement of established dosing regimens, not only the plasma but also the tissue pharmacokinetics of the drug have to be considered. For the current paper, almost 7000 scientific articles were identified and screened from which 429 were reviewed in detail and 100 were included in this paper. Systemic pharmacokinetics are available for most antiparasitic drugs but in many cases, not for all the relevant patient populations and only for single-or multiple-dose administration. Systemic pharmacokinetic data in patients with organ impairment and target-site pharmacokinetic data for relevant tissues and body fluids are mostly lacking. To improve the treatment of patients with parasitic diseases, research in these areas is urgently needed.

show abstract

Pharmacokinetics of amphotericin B lipid complex in critically ill patients undergoing continuous venovenous haemodiafiltration

Cited by 12 publications

References 14 publications

Recommendation of Antimicrobial Dosing Optimization During Continuous Renal Replacement Therapy

Recommendation of Antimicrobial Dosing Optimization During Continuous Renal Replacement Therapy

Nanoantibiotics containing membrane-active human cathelicidin LL-37 or synthetic ceragenins attached to the surface of magnetic nanoparticles as novel and innovative therapeutic tools: current status and potential future applications

Systemic and Target-Site Pharmacokinetics of Antiparasitic Agents

Contact Info

Product

Resources

About